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Abstract: Burden of disease: South East Asia, and India in partic-
ular, is reported to have thehighest burdenof community-acquired
pneumonia (CAP) in children <5 years of age. Annually there are
about 43million newCAP. According toNHFS-3, CAP in preceding 2
weekswas reported in5.8% children.About10%of acute respiratory
illnesses are classiﬁed as CAP, translating into 0.2 -0.5 episodes per
child-year and approximately 10 to 20 per cent of these episodes
tend tobesevere. IndiahasaCAPmortality rateof about322per100
000 under-ﬁve population. Mortality varies by severity of disease,
ranging from 1% - 15.8%.
Health care seekingpractices: Awasthi et al (2015) reported that
fast breathing, an early sign of CAP, was not commonly recognized
by care givers as well as grass root health care providers. Also, they
did not look of respiratory rate and chest in-drawing. Village based
rural medical practitioner was the preferred health-care provider.
By the time the most serious cases reached a public tertiary-
care hospital, children had been ill for a week and treated by 2-3
providers. Quality of care at government facilitieswasdeemedpoor
by caregivers. Similar situation is seen across the country.
Causative organisms: A few studies done in India to assess the
etiological organisms of CAP have reported low yield of blood cul-
tures (about 2%) and higher yield of nasopharyngeal swabs (NPS)
(13.7 - 40%) for bacteria, namely Streptococcus pneumoniae (SP),
Hemophilus inﬂuenza and Staphylococcus aureus (SA)). In blood cul-
ture, however, the leading organism was SA followed by SP. The
studies have reported high yield of viruses from NPS. Hence mixed
viral andbacterial infections resulting in CAPpresentationhas been
speculated.
Associates of mortality: In India CAP related mortality is associ-
atedwithmalnutrition, anemia, younger age, delayed care seeking,
lower spO2 <95% and presence of consolidation on Chest X-ray.
Existing CAP Management scenario: The Government of India is
largelymoving from theuse of co-trimoxazole to that of amoxicillin
for the treatmentof CAP, as recommendedby theUNICEF.However,
adherence of these guidelines is poor by medical practitioners. The
public health facilities like the CHC and the PHC are not admitting
cases of pediatric CAP in the high burden states of India.
Future Directions: It is essential to work for the primary pre-
vention of CAP by adequate immunization, improving nutritional
status and hygiene. Community awareness about CAP has to
increase and public health system has to be responsive and patient
friendly. There has to adherence to CAP treatment guidelines. These
initiatives must be taken simultaneously, early and effectively.
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Abstract: Pneumonia is the most important killer of chil-
dren <5 years old nowadays and the most important bacterial
organism in early childhood pneumonia is S. pneumoniae. When
trying to determine the extent of potential reduction of pneumo-
nia burden in children one encounters real difﬁculties, some of
which are the absence of deﬁnition of pneumonia, the absence
of radiologic diagnosis of pneumonia, the differences between
populations, the paucity of positive cultures and environmen-
tal considerations that could determine outcome of pneumonia
and antibiotic use. Initially, efﬁcacy studies were aimed mainly
at invasive pneumococcal pneumonia (S. pneumoniae usually iso-
lated from blood or pleural ﬂuid) or alveolar pneumonia (mostly
identiﬁed with bacterial pneumonia when organisms were not
included). However, using PCVs, we have learned within 2 decades
from a variety of advanced studies and introduction to the National
Immunization Program, that PCVs impact on prevention of respi-
ratory infections much beyond what was expected (Using PCVs
to learn about pneumococcal involvement in disease and vaccina-
tion impact is termed “PCV vaccine probe studies”). We currently
can point out to the remarkable impact of PCVs on the following
pneumonia-related endpoints: Reduction of invasive pneumococ-
cal pneumonia, culture-negative alveolar pneumonia, all-cause
pneumonia, all-cause lower respiratory infections, bacterial-viral
mixed infections, pleuropneumonia and more. Moreover, PCVs
reduce carriage and spread of vaccine type pneumococcal strains,
resulting in protection not only among the vaccinated children but
also from diseases in all ages (herd protection). Inﬂuenza vaccines
may in turn reduce pneumonia through the reduction of acute
inﬂuenza illness, often responsible for severe secondary bacterial
infections. However, studies demonstrating this effect are lagging
behind the studies with PCVs.
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